<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604002</url>
  </required_header>
  <id_info>
    <org_study_id>S-2020-5</org_study_id>
    <nct_id>NCT04604002</nct_id>
  </id_info>
  <brief_title>Evaluation of Additional Heidelberg Engineering SPECTRALIS With OCT Angiography Module (OCTA Module) Scan Types</brief_title>
  <acronym>OCTA</acronym>
  <official_title>Evaluation of Additional Heidelberg Engineering SPECTRALIS With OCT Angiography Module (OCTA Module) Scan Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg Engineering GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg Engineering GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of image quality and clinical relevance of OCT Angiography at different speed/ART&#xD;
      combinations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
      1.) Compare the image quality between the predicate scan types and the corresponding&#xD;
      investigational scan types.&#xD;
&#xD;
      2. Compare the visibility of key anatomical vascular structures between the predicate scan&#xD;
      types and the corresponding investigational scan types.&#xD;
&#xD;
      3. Assess the agreement in identification of vascular abnormalities between the predicate&#xD;
      scan types and the corresponding investigational scan types, where agreement is assessed by&#xD;
      the vascular abnormalities identified from the predicate scan types.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image quality score</measure>
    <time_frame>through study completion, an average of 1 day</time_frame>
    <description>Graded 0-2 (0 = poor, 1 = average, 2 = good)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visibility of OCTA key anatomical vascular structures quality score</measure>
    <time_frame>through study completion, an average of 1 day</time_frame>
    <description>Graded 0-2 (easy (2), difficult (1) or unable to be distinguished (0)) based on pre-specified abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of vascular abnormalities on OCTA</measure>
    <time_frame>through study completion, an average of 1 day</time_frame>
    <description>Graded Yes, No, or Unable to Grade based on pre-specified abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>through study completion, an average of 1 day</time_frame>
    <description>All AEs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Retinal Vascular</condition>
  <condition>Normal Eyes</condition>
  <arm_group>
    <arm_group_label>Subjects with Normal Eyes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects without ophthalmic pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with Pathology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects with retinal vascular pathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT Angiography</intervention_name>
    <description>OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.</description>
    <arm_group_label>Subjects with Normal Eyes</arm_group_label>
    <arm_group_label>Subjects with Pathology</arm_group_label>
    <other_name>Optical Coherence Tomography Angiography</other_name>
    <other_name>OCTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Color Fundus Photography</intervention_name>
    <description>Non-contact white light photography</description>
    <arm_group_label>Subjects with Normal Eyes</arm_group_label>
    <arm_group_label>Subjects with Pathology</arm_group_label>
    <other_name>CFP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>A non-contact test that uses light waves to take cross-sectional pictures of the retina</description>
    <arm_group_label>Subjects with Normal Eyes</arm_group_label>
    <arm_group_label>Subjects with Pathology</arm_group_label>
    <other_name>OCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All Populations:&#xD;
&#xD;
               1. Able and willing to undergo the test procedures, sign informed consent, and&#xD;
                  follow instructions.&#xD;
&#xD;
               2. Age ≥ 22&#xD;
&#xD;
          -  Normal Population:&#xD;
&#xD;
             3. Subjects without uncontrolled systemic conditions, as determined by the&#xD;
             Investigator 4. Subjects without ocular disease, as determined by the Investigator 5.&#xD;
             Corrected visual acuity ≥ 20/40 6. No reported history of ocular surgical intervention&#xD;
             (except for refractive or cataract surgery)&#xD;
&#xD;
          -  Pathology Population:&#xD;
&#xD;
             3. Subjects with vascular abnormalities such as retinal ischemia, microaneurysms,&#xD;
             choroidal neovascularization, retinal neovascularization in at least one eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All Populations:&#xD;
&#xD;
               1. Subjects unable to read or write&#xD;
&#xD;
               2. Subjects with ocular media not sufficiently clear to obtain acceptable&#xD;
                  study-related imaging&#xD;
&#xD;
               3. Subjects who cannot tolerate the imaging procedures&#xD;
&#xD;
               4. Subjects without an accompanying structural OCT and CFP image for an acceptable&#xD;
                  OCTA image&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeast Retina Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Oakes</last_name>
    <phone>508-570-8553</phone>
    <email>heather.oakes@heidelbergengineering.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Anne Hurst</last_name>
      <phone>706-650-0061</phone>
      <email>jenniferanne@southeastretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Siobhan Ortiz</last_name>
      <phone>706-650-0061</phone>
      <email>siobhan@southeastretina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

